StocksMedium•16 November 2026•
1 min read
FDA Approves Teva's IGALMI for At-Home Use in Acute Agitation
Key Facts
1The U.S. FDA approved Teva's IGALMI sublingual film as the first at-home treatment for acute agitation in adults with schizophrenia or bipolar disorder.
The U.S. FDA approved Teva's IGALMI sublingual film as the first at-home treatment for acute agitation in adults with schizophrenia or bipolar disorder. Benzinga reported that the approval covers the use of the treatment for patients with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
TEVA closed at $44.5 on November 13, 2026, as the regulatory milestone shifts the administration of the drug from clinical settings to home use. The approval addresses acute agitation episodes that can escalate quickly, providing a self-administration option for conditions that previously lacked FDA-approved at-home treatments.